MK-1454 in a phase II trial for HER2+ breast cancer extended mPFS by 3.1 months when combined with trastuzumab and chemotherapy, though with a 18% incidence of grade 3+ febrile neutropenia (31). The gene discussed is ERBB2; the disease is breast cancer.